CRISPR Therapeutics(US:CRSP)2025-05-06 20:05Clinical Trials and Investigational Therapies - CTX310™ Phase 1 clinical trial shows dose-dependent reductions in triglycerides (TG) of up to 82% and low-density lipoprotein (LDL) of up to 81%[1] - CTX320™ targeting the LPA gene is in an ongoing Phase 1 clinical trial, with top-line data expected in Q2 2025[1] - CTX112™ and CTX131™ are in clinical trials targeting CD19 and CD70, with updates anticipated in 2025[1] - CTX211, an investigational therapy for type 1 diabetes, is currently in a Phase 1 clinical trial[18] - The company is advancing its investigational therapies, including CTX310 and CTX320, which are in ongoing clinical trials for cardiovascular diseases[17] Financial Performance - Cash, cash equivalents, and marketable securities totaled $1.86 billion as of March 31, 2025, down from $1.90 billion at the end of 2024[15] - R&D expenses for Q1 2025 were $72.5 million, a decrease from $76.2 million in Q1 2024, primarily due to lower employee-related expenses[15] - General and administrative expenses increased to $19.3 million in Q1 2025 from $18.0 million in Q1 2024[15] - Collaboration expenses rose to $57.5 million in Q1 2025, compared to $47.0 million in Q1 2024, mainly due to costs related to CASGEVY[15] - Net loss for Q1 2025 was $136.0 million, compared to a net loss of $116.6 million in Q1 2024[15] - Total revenue for Q1 2025 was $865,000, an increase from $504,000 in Q1 2024, representing a 71.5% growth[26] - Research and development expenses for Q1 2025 were $72,484,000, a decrease from $76,172,000 in Q1 2024, reflecting a 4.5% reduction[26] - Net loss for Q1 2025 was $135,996,000, compared to a net loss of $116,591,000 in Q1 2024, indicating a 16.7% increase in losses[26] - Cash and cash equivalents as of March 31, 2025, were $235,184,000, down from $298,257,000 as of December 31, 2024[28] - Total assets decreased to $2,166,102,000 as of March 31, 2025, from $2,242,034,000 as of December 31, 2024[28] - The comprehensive loss for Q1 2025 was $133,701,000, compared to a comprehensive loss of $120,056,000 in Q1 2024[26] Product Approvals and Market Activity - As of May 1, over 65 authorized treatment centers (ATCs) activated globally for CASGEVY®, with approximately 90 patients having cells collected[7] - CASGEVY® is approved in multiple jurisdictions, with ongoing launches and a manufacturing license application submitted to the FDA[7] - The company celebrated the approval of CASGEVY® (exa-cel) in several countries for treating sickle cell disease and transfusion-dependent beta thalassemia[19] Strategic Partnerships - CRISPR Therapeutics has formed strategic partnerships with leading companies, including Vertex Pharmaceuticals, to accelerate its efforts[19]